Abstract
Many hospital laboratories have technical capacity to perform whole-genome sequencing but lack bioinformatic expertise to analyse sequence data. Sending isolates to reference laboratories creates delays that can be highly detrimental to outbreak responses. The Wellington Regional Hospital laboratory, which lacks on-site bioinformaticians, implemented real-time nanopore-based genomic surveillance that has detected several hospital outbreaks at an early stage. This has required off-site analysis, often taking weeks. Solu Genomics, a cloud-based automated bioinformatic platform, requires no bioinformatic or command-line expertise and accepts basecalled sequence files or genome assemblies. This study aimed to use Solu to replicate the analysis of two prior neonatal unit outbreaks detected by on-site genomic surveillance, as if they had occurred now, and compare the output to ‘manual’ bioinformatic analysis. Surveillance isolates that had been sequenced up until the beginning of each outbreak were loaded into Solu to replicate the background genomic data available when each outbreak occurred. The 13 methicillin-resistant Staphylococcus aureus (MRSA) and seven Klebsiella variicola outbreak isolates were then uploaded. Including upload time, each Solu analysis was completed in under 40 minutes. The phylogenetic trees generated showed distinct clustering of outbreak isolates, with overall tree topologies similar to the manual analyses. Median pairwise single-nucleotide variant distances were 12 (range 4-27) and 6 (range 1-11) for the MRSA and K. variicola outbreaks, respectively, versus 6 (range 0-14) and 18 (range 0-54) for the manual analyses. This study demonstrates that Solu Genomics can provide high-resolution, actionable outbreak analysis within minutes, without the need for bioinformatic expertise.
Importance Outbreaks in healthcare settings present serious risks to patient safety and can disrupt healthcare delivery. Timely and precise detection of these outbreaks is essential for effective infection prevention and control as well as reducing patient harm and service disruptions. This study emphasises the value of an intuitive cloud-based bioinformatics platform, in overcoming a key obstacle to the widespread adoption of whole-genome sequencing in hospital laboratories: bioinformatic analyses. Our research highlights the practicality of real-time genomic monitoring in local laboratories by showing that a non-specialist platform can produce results that complement and align with manual analyses while offering significant time savings. This approach can accelerate the detection and subsequent control of outbreaks caused by organisms like methicillin-resistant Staphylococcus aureus and Klebsiella variicola, ultimately improving patient outcomes and healthcare efficiency.
Competing Interest Statement
RTW received travel expenses from Oxford Nanopore Technologies to attend their annual, London Calling, meeting in May 2024 (as do all speakers). RTW received a travel bursary from Oxford Nanopore Technologies and a travel grant from the UK Microbiology Society to present at conferences. The authors declare no other conflicts of financial, general, or institutional competing interests.
Funding Statement
This study was supported by internal departmental funds at Awanui Laboratories Wellington, the Institute of Environmental Science and Research (ESR), and Genomics Aotearoa through funding from the Ministry of Business Innovation and Employment (MBIE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analysis and reporting of this outbreak constituted an 'audit or related activity' as per New Zealand Health and Disability Ethics Committees, so did not require review. The study was screened by the Health and Disability Ethics Committees (HDEC) of New Zealand after which further review was waived (2025 OOS 22308)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos